81 – 100 of 109
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
(
- Contribution to journal › Article
-
Mark
Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2006
-
Mark
Mechanisms of L-DOPA-induced dyskinesia in Parkinson´s disease: What do animal models tell us?
2006) p.351-360(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Dyskinesia and neural grafting in Parkinson's disease
2006) p.184-224(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
(
- Contribution to journal › Letter
-
Mark
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
(
- Contribution to journal › Article
-
Mark
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
(
- Contribution to journal › Article
-
Mark
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
(
- Contribution to journal › Article
- 2005
-
Mark
Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.
(
- Contribution to journal › Article
-
Mark
Chapte B7 - Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease
2005) p.193-208(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
- 2004
-
Mark
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
(
- Contribution to journal › Article
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
(
- Contribution to journal › Article
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism
(
- Contribution to journal › Article
- 2003
-
Mark
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article